Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study
- 194 Downloads
Background Coxibs cardiovascular (CV) safety continues being a current issue after rofecoxib worldwide withdrawal in 2004. Objective To evaluate the cardiovascular and gastrointestinal (GI) risk of coxibs through case/non-case study. Setting The Spanish Pharmacovigilance System for Human Use Drugs (FEDRA) and the Uppsala Monitoring Centre (VigiBase) databases. Method We identified adverse drug reactions (ADRs) cases reported under the MedDRA system organ classes of “cardiac disorders”, “vascular disorders”, “nervous system disorder” and “gastrointestinal disorders”. Disproportionality was considered when the following criteria were met simultaneously: proportional reporting ratio (PRR) ≥ 2, 95% confidence interval lower limit of reporting odds ratio (ROR) > 1, Chi square test (χ2) ≥ 4; and number of ADR reports (n rep.) > 3. Main outcome measure Potential disproportionality between cardiovascular and GI ADRs as reported to FEDRA and VigiBase and the use of coxibs. Results We found association between coxibs and CV-ADRs in FEDRA [PRR 2.11 (95% CI 1.97–2.27); ROR 2.53 (95% CI 2.29–2.89); χ2 367.81; n rep., 561] and VigiBase [PRR 2.67 (95% CI 2.64–2.71); ROR 3.26 (95% CI 3.20–3.31); χ2 23,950.93; n rep., 21,047]; and between coxibs and GI-ADRs in VigiBase [PRR 2.91 (95% CI 2.84–2.97); ROR 3.08 (95% CI 3.01–3.16); χ2 8762.82; n rep. 6954]. No association was found between coxibs and GI-ADRs in FEDRA. Conclusion The association found support a potential coxibs class effect in terms of cardiovascular safety. Classical NSAIDs GI risk may be higher than that for coxibs.
KeywordsCardiovascular disease Cyclooxygenase 2 inhibitors Epidemiologic study Gastrointestinal disease Non steroidal anti inflammatory agents
No funding was received for preparation of the manuscript.
Conflicts of interest
The authors declare that they have no conflicts of interest.
- 3.Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis The CLASS Study: a randomized controlled trial. JAMA. 2000;284:1247–55.CrossRefPubMedGoogle Scholar
- 4.Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368:1771–81.CrossRefPubMedGoogle Scholar
- 13.VigiLyze. Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. 2017. https://www.who-umc.org/vigibase/vigilyze/. Accessed 30 Apr 2018.
- 15.Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. 2018. https://www.who-umc.org/global-pharmacovigilance/members/who-programme-members/. Accessed 20 May 2018.
- 20.Aronson JK. Side effects of drugs annual: a worldwide yearly survey of new data and trends in adverse drug reactions. 1st ed. London: Elsevier; 2011.Google Scholar
- 23.Sommet A, Grolleau S, Bagheri H, Lapeyre-Mestre M, Montastruc JL. French Network of Regional Pharmacovigilance Centres. Was the thrombotic risk of rofecoxib predictible from the French Pharmacovigilance Database before 30 September 2004? Eur J Clin Pharmacol. 2008;64:829–34.CrossRefPubMedGoogle Scholar
- 27.Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol. 2013;48:830–8.CrossRefPubMedGoogle Scholar
- 30.Zeng C, Wei J, Li H, Yang T, Gao SG, Li YS, et al. Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis. Sci Rep. 2015;5:1–13.Google Scholar
- 32.European Medicines Agency. Post-authorisation evaluation of medicines for human use. Public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018391.pdf. Accessed 11 July 2018.
- 33.Government of Canada HC. Summary Safety Review—Celecoxib (CELEBREX and generics)—assessing the risk of serious heart and stroke side effects at high doses relative to other non-steroidal anti-inflammatory drugs (NSAIDs). 2016. http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/celecoxib-eng.php. Accessed 28 Apr 2018.
- 34.Laporte J-R, Capellà D. European medicines research: perspectives in pharmacotoxicology and pharmacovigilance. In: Fracchia GN, editor. Biomedical and health research. Amsterdam: IOS Press; 1994. p. 370-90. ISBN: 90-5199-154-1.Google Scholar